nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.10.2010 | Review

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

verfasst von: Anne M. Friel, Claire Corcoran, John Crown, Lorraine O’Driscoll

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Early detection of cancer is vital to improved overall survival rates. At present, evidence is accumulating for the clinical value of detecting occult tumor cells in peripheral blood, plasma, and serum specimens from cancer patients. Both molecular and cellular approaches, which differ in sensitivity and specificity, have been used for such means. Circulating tumor cells and extracellular nucleic acids have been detected within blood, plasma, and sera of cancer patients. As the presence of malignant tumors are clinically determined and/or confirmed upon biopsy procurement—which in itself may have detrimental effects in terms of stimulating cancer progression/metastases—minimally invasive methods would be highly advantageous to the diagnosis and prognosis of breast cancer and the subsequent tailoring of targeted treatments for individuals, if reliable panels of biomarkers suitable for such an approach exist. Herein, we review the current advances made in the detection of such circulating tumor cells and nucleic acids, with particular emphasis on extracellular nucleic acids, specifically extracellular mRNAs and discuss their clinical relevance.

Jemal A et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96PubMedCrossRef

Perou C et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef

Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790–800PubMedCrossRef

Jiang WG et al (2002) Molecular detection of micro-metastasis in breast cancer. Crit Rev Oncol Hematol 43(1):13–31PubMedCrossRef

Gilbey AM et al (2004) The detection of circulating breast cancer cells in blood. J Clin Pathol 57(9):903–911PubMedCrossRef

Pantel K, Brakenhoff R (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4(6):448–456PubMedCrossRef

Al-Hajj M et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988PubMedCrossRef

Zhang S et al (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68(11):4311–4320PubMedCrossRef

Baba T et al (2009) Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28(2):209–218PubMedCrossRef

10.

Curley M et al (2009) CD133 Expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 27(12):2875–2883PubMed

11.

Rutella S et al (2009) Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 15(13):4299–4311PubMedCrossRef

12.

Ashworth T (1869) A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 14:146–147

13.

Allan AL, Keeney M (2010) Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol 2010:426218PubMed

14.

Liu M et al (2009) Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 27(31):5153–5159PubMedCrossRef

15.

Cristofanilli M et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791PubMedCrossRef

16.

Budd G et al (2006) Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res 12(21):6403–6409PubMedCrossRef

17.

Hayes D et al (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12(141):4218–4224PubMedCrossRef

18.

Pierga J et al (2008) Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 14(21):7004–7010PubMedCrossRef

19.

Harris L et al (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312PubMedCrossRef

20.

Nagrath S et al (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173):1235–1239PubMedCrossRef

21.

Tewes M et al (2009) Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 115(3):581–590PubMedCrossRef

22.

Alix-Panabières C et al (2005) Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 299(1–2):177–188PubMedCrossRef

23.

Alix-Panabières C et al (2007) Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 53(3):537–539PubMedCrossRef

24.

Fehm T et al (2009) Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 11(4):R59PubMedCrossRef

25.

Fehm T et al (2007) Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 9(5):R74PubMedCrossRef

26.

Alunni-Fabbroni M, Sandri M (2010) Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods 50(4):289–297PubMedCrossRef

27.

Vona G et al (2000) Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 156(1):57–63PubMed

28.

Gertler R et al (2003) Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res 162:149–155PubMed

29.

Müller V et al (2005) Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11(10):3678–3685PubMedCrossRef

30.

Naume B et al (2004) Detection of isolated tumor cells in peripheral blood and in BM: evaluation of a new enrichment method. Cytotherapy 6(3):244–252PubMedCrossRef

31.

Hayes G et al (2010) Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: validation of a simplified method suitable for multi-center clinical studies. Leuk Res 34(6):809–815

32.

Mostert B et al (2009) Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 35(5):463–474PubMedCrossRef

33.

Cristofanilli M, Braun S (2010) Circulating tumor cells revisited. JAMA 303(11):1092–1093PubMedCrossRef

34.

Fehm T et al (2005) Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 7(2):171–185PubMedCrossRef

35.

Austrup F et al (2000) Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. Br J Cancer 83(12):1664–1673PubMedCrossRef

36.

Fehm T et al (2002) Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 8(7):2073–2084PubMed

37.

Meng S et al (2006) uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 103(46):17361–17365PubMedCrossRef

38.

Meng S et al (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 101(25):9393–9398PubMedCrossRef

39.

Pantel K et al (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8(5):329–340PubMedCrossRef

40.

Braun S et al (2009) The prognostic impact of bone marrow micrometastases in women with breast cancer. Cancer Invest 27(6):598–603PubMedCrossRef

41.

Braun S et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802PubMedCrossRef

42.

Janni W et al (2005) The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 103(5):884–891PubMedCrossRef

43.

Krawczyk N et al (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res 29(10):4019–4024PubMed

44.

Mandel P, Metais P (1948) Les acides nucleiques du plasma sanguine chez l’homme (in French). C R Seances Soc Biol Fil 142(3–4):241–243PubMed

45.

Tan EM et al (1966) Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 45(11):1732–1740PubMedCrossRef

46.

Koffler D et al (1973) The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. J Clin Invest 52(1):198–204PubMedCrossRef

47.

Leon S et al (1977) Free DNA in the serum of rheumatoid arthritis patients. J Rheumatol 4(2):139–143PubMed

48.

Leon S et al (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37(3):646–650PubMed

49.

Stroun M et al (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46(5):318–322PubMedCrossRef

50.

Sorenson G et al (1994) Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 3(1):67–71

51.

Vasioukhin V et al (1994) Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 86(4):774–779PubMedCrossRef

52.

Kohler C et al (2009) Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer 8:105PubMedCrossRef

53.

Divella R et al (2009) Circulating hTERT DNA in early breast cancer. Anticancer Res 29(7):2845–2849PubMed

54.

Van der Auwera I et al (2009) The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer 100(8):1277–1286PubMedCrossRef

55.

van der Drift M et al (2010) Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 68(2):283–287PubMedCrossRef

56.

Yoon K et al (2009) Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn 11(3):182–185PubMedCrossRef

57.

Yen L et al (2009) Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 15(13):4508–4513PubMedCrossRef

58.

Ellinger J et al (2009) CpG island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J Urol 182(1):324–329PubMedCrossRef

59.

Board R et al (2009) Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer 101(10):1724–1730PubMedCrossRef

60.

Chuang T et al (2010) Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck 32(2):229–234PubMed

61.

Schwarzenbach H et al (2009) Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res 11(5):R71PubMedCrossRef

62.

Marrakchi R et al (2008) Detection of cytokeratin 19 mRNA and CYFRA 21-1 (cytokeratin 19 fragments) in blood of Tunisian women with breast cancer. Int J Biol Markers 23(4):238–243

63.

García V et al (2008) Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett 263(2):312–320PubMedCrossRef

64.

O’Driscoll L et al (2008) Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR. Cancer Genomics Proteomics 5(2):94–104PubMed

65.

Terrin L et al (2008) Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res 14(22):7444–7451PubMedCrossRef

66.

Vrieling A et al (2009) Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels. Growth Horm IGF Res 19(2):126–135PubMedCrossRef

67.

Fleischhacker M, Schmidt B (2007) Circulating nucleic acids (CNAs) and cancer—a survey. Biochim Biophys Acta 1775(1):181–232PubMed

68.

Rieber M, Bacalao J (1974) An “external” RNA removable from mammalian cells by mild proteolysis. Proc Natl Acad Sci USA 71(12):4960–4964PubMedCrossRef

69.

Laktionov PP et al (2004) Cell-surface-bound nucleic acids: free and cell-surface-bound nucleic acids in blood of healthy donors and breast cancer patients. Ann NY Acad Sci 1022:221–227PubMedCrossRef

70.

Chelobanov BP et al (2004) Isolation of nucleic acid binding proteins: an approach for isolation of cell surface, nucleic acid binding proteins. Ann NY Acad Sci 1022:239–243PubMedCrossRef

71.

Wieczorek AJ, Rhyner K (1989) A gene probe test for serum RNA proteolipid in neoplasia. Schweiz Med Wochenschr 119(39):1342–1343PubMed

72.

Wieczorek AJ et al (1985) Isolation and characterization of an RNA–proteolipid complex associated with the malignant state in humans. Proc Natl Acad Sci USA 82(10):3455–3459PubMedCrossRef

73.

Hasselmann DO et al (2001) Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 47(8):1488–1489PubMed

74.

Stroun M et al (1978) Presence of RNA in the nucleoprotein complex spontaneously released by human lymphocytes and frog auricles in culture. Cancer Res 38(10):3546–3554PubMed

75.

Jachertz D et al (1979) Information carried by the DNA released by antigen-stimulated lymphocytes. Immunology 37(4):753–763PubMed

76.

Anker P et al (1999) Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 18(1):65–73PubMedCrossRef

77.

Jahr JS et al (2001) A novel approach to measuring circulating blood volume: the use of a hemoglobin-based oxygen carrier in a rabbit model. Anesth Analg 92(3):609–614PubMedCrossRef

78.

Skog J et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10(12):1470–1476PubMedCrossRef

79.

Wright LC et al (1986) A proteolipid in cancer cells is the origin of their high-resolution NMR spectrum. FEBS Lett 203(2):164–168PubMedCrossRef

80.

Rosi A et al (1988) RNA–lipid complexes released from the plasma membrane of human colon carcinoma cells. Cancer Lett 39(2):153–160PubMedCrossRef

81.

Ceccarini M et al (1989) Biochemical and NMR studies on structure and release conditions of RNA-containing vesicles shed by human colon adenocarcinoma cells. Int J Cancer 44(4):714–721PubMedCrossRef

82.

Ratajczak J et al (2006) Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 20(9):1487–1495PubMedCrossRef

83.

Graner MW et al (2009) Proteomic and immunologic analyses of brain tumor exosomes. FASEB J 23(5):1541–1557PubMedCrossRef

84.

Thery C et al (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2(8):569–579PubMed

85.

Keller S et al (2006) Exosomes: from biogenesis and secretion to biological function. Immunol Lett 107(2):102–108PubMedCrossRef

86.

Calzolari A et al (2006) TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. J Cell Sci 119(Pt 21):4486–4498PubMedCrossRef

87.

Valadi H et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9(6):654–659PubMedCrossRef

88.

Safaei R et al (2005) Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 4(10):1595–1604PubMedCrossRef

89.

Chaput N et al (2005) The potential of exosomes in immunotherapy. Expert Opin Biol Ther 5(6):737–747PubMedCrossRef

90.

Liu C et al (2006) Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 176(3):1375–1385PubMed

91.

Ginestra A et al (1998) The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res 18(5A):3433–3437PubMed

92.

Clayton A et al (2007) Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 67(15):7458–7466PubMedCrossRef

93.

Ng EK et al (2002) Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem 48(8):1212–1217PubMed

94.

O’Driscoll L (2007) Extracellular nucleic acids and their potential as diagnostic, prognostic and predictive biomarkers. Anticancer Res 27(3):1257–1265PubMed

95.

Rabinowits G et al (2009) Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10(1):42–46PubMedCrossRef

96.

Silva JM et al (2001) Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res 7(9):2821–2825PubMed

97.

Chen X et al (2000) Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 6(10):3823–3826PubMed

98.

Silva J et al (2007) Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res 9(4):R55PubMedCrossRef

99.

Fuchs E, Weber K (1994) Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem 63:345–382PubMed

100.

Dohmoto K et al (2001) The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21–1) in human lung cancer cell lines. Int J Cancer 91(4):468–473PubMedCrossRef

101.

Pujol JL et al (1993) Serum fragment of cytokeratin subunit 19 measured by CYFRA 21–1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53(1):61–66PubMed

102.

Ravdin PM et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19(4):980–991PubMed

103.

Stathopoulou A et al (2002) Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 20(16):3404–3412PubMedCrossRef

104.

Xenidis N et al (2006) Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 24(23):3756–3762PubMedCrossRef

105.

Daskalaki A et al (2009) Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer 101(4):589–597PubMedCrossRef

106.

Xenidis N et al (2003) Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14(6):849–855PubMedCrossRef

107.

Quintela-Fandino M et al (2006) Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. J Clin Oncol 24(22):3611–3618PubMedCrossRef

108.

Wiedswang G et al (2004) Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 10(16):5342–5348PubMedCrossRef

109.

Ignatiadis M et al (2008) Circulating tumor cells in breast cancer. Curr Opin Obstet Gynecol 20(1):55–60PubMedCrossRef

110.

Alix-Panabieres C et al (2009) Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 11(3):R39PubMedCrossRef

111.

DePinho R (2000) The age of cancer. Nature 408(6809):248–254PubMedCrossRef

112.

Dasí F et al (2006) Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Ann NY Acad Sci 1075:204–210PubMedCrossRef

113.

Li H et al (2009) Relationship between the expression of hTERT and EYA4 mRNA in peripheral blood mononuclear cells with the progressive stages of carcinogenesis of the esophagus. J Exp Clin Cancer Res 28:145PubMedCrossRef

114.

Elder E et al (2003) KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod Pathol 16(3):246–255PubMedCrossRef

115.

Shen C et al (2009) The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR. Clin Biochem 42(3):194–200PubMedCrossRef

116.

Jacobs JJ, van Lohuizen M (2002) Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 1602(2):151–161PubMed

117.

Raaphorst FM (2005) Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors. Hum Mol Genet 14 Spec No 1, R93–R100

118.

Song LB et al (2009) The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial–mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest 119(12):3626–3636PubMedCrossRef

119.

Bachmann IM et al (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24(2):268–273PubMedCrossRef

120.

Kleer CG et al (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100(20):11606–11611PubMedCrossRef

121.

van Lohuizen M et al (1991) Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65(5):737–752PubMedCrossRef

122.

Liu S et al (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66(12):6063–6071PubMedCrossRef

123.

Kim JH et al (2004) Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 13(5):383–388PubMedCrossRef

124.

Vonlanthen S et al (2001) The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 84(10):1372–1376PubMedCrossRef

125.

Kim JH et al (2004) The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203(2):217–224PubMedCrossRef

126.

Klug J et al (2000) Uteroglobin/Clara cell 10-kDa family of proteins: nomenclature committee report. Ann NY Acad Sci 923:348–354PubMedCrossRef

127.

Ni J et al (2000) All human genes of the uteroglobin family are localized on chromosome 11q12.2 and form a dense cluster. Ann NY Acad Sci 923:25–42PubMedCrossRef

128.

Watson MA, Fleming TP (1994) Isolation of differentially expressed sequence tags from human breast cancer. Cancer Res 54(17):4598–4602PubMed

129.

Watson MA et al (1998) Structure and transcriptional regulation of the human mammaglobin gene, a breast cancer associated member of the uteroglobin gene family localized to chromosome 11q13. Oncogene 16(6):817–824PubMedCrossRef

130.

Tassi RA et al (2008) Mammaglobin B expression in human endometrial cancer. Int J Gynecol Cancer 18(5):1090–1096PubMedCrossRef

131.

Watson MA, Fleming TP (1996) Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 56(4):860–865PubMed

132.

Zafrakas M et al (2006) Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies. BMC Cancer 6:88PubMedCrossRef

133.

Nunez-Villar MJ et al (2003) Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype. Breast Cancer Res 5(3):R65–R70PubMedCrossRef

134.

Fleming TP, Watson MA (2000) Mammaglobin, a breast-specific gene, and its utility as a marker for breast cancer. Ann NY Acad Sci 923:78–89PubMedCrossRef

135.

Fanger GR et al (2002) Detection of mammaglobin in the sera of patients with breast cancer. Tumour Biol 23(4):212–221PubMedCrossRef

136.

Zach O et al (1999) Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J Clin Oncol 17(7):2015–2019PubMed

137.

Cerveira N et al (2004) Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer patients. Int J Cancer 108(4):592–595PubMedCrossRef

138.

Marques AR et al (2009) Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence. Breast Cancer Res Treat 114(2):223–232PubMedCrossRef

139.

Mikhitarian K et al (2008) Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: interim results of a prospective cohort study. BMC Cancer 8:55PubMedCrossRef

140.

Fu M et al (2004) Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145(12):5439–5447PubMedCrossRef

141.

Butt AJ et al (2005) Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12(Suppl 1):S47–S59PubMedCrossRef

142.

Carney WP et al (2004) Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 5(2):105–116PubMedCrossRef

143.

Apostolaki S et al (2009) Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Res Treat 117(3):525–534PubMedCrossRef

144.

Ambros V (2004) The functions of animal microRNAs. Nature 431(7006):350–355PubMedCrossRef

145.

Hennessy E, O’Driscoll L (2008) Molecular medicine of microRNAs: structure, function and implications for diabetes. Expert Rev Mol Med 10:e24PubMedCrossRef

146.

Gartel A, Kandel E (2008) miRNAs: Little known mediators of oncogenesis. Semin Cancer Biol 18(2):103–110PubMedCrossRef

147.

Lawrie C et al (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141(5):672–675PubMedCrossRef

148.

Mitchell P et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513–10518PubMedCrossRef

149.

Chen X et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006PubMedCrossRef

150.

Taylor D, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110(1):13–21PubMedCrossRef

151.

Heneghan H et al (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 251(3):499–505PubMedCrossRef

152.

Duffy M (2005) Predictive markers in breast and other cancers: a review. Clin Chem 51(3):494–503PubMedCrossRef

153.

Gasparini G et al (2006) Is tailored therapy feasible in oncology? Crit Rev Oncol Hematol 57(1):79–101PubMedCrossRef

154.

Hayes D (2005) Prognostic and predictive factors for breast cancer: translating technology to oncology. J Clin Oncol 23(8):1596–1597PubMedCrossRef

155.

McShane L et al (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23(36):9067–9072PubMedCrossRef

156.

Barker AD et al (2009) I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86(1):97–100PubMedCrossRef

157.

Pepe MS et al (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93(14):1054–1061PubMedCrossRef

Titel: Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer
verfasst von: Anne M. Friel
Claire Corcoran
John Crown
Lorraine O’Driscoll
Publikationsdatum: 01.10.2010
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0980-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients

NAT2 polymorphisms combining with smoking associated with breast cancer susceptibility: a meta-analysis

Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?

Inhibition of mammary tumor growth by estrogens: is there a specific role for estrogen receptors alpha and beta?

Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer

Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie